Analyst consensus rating
Halozyme Therapeutics Analyst Rating: Buy
Direct answer
Halozyme Therapeutics's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $99.56.
Forecast evidence checked September 22, 2026.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $111.45
- Average price target
- $99.56
- High price target
- $115.00
- Low price target
- $70.00
- Low target gap
- -37.2%
- Target upside
- -10.7%
- High target gap
- +3.2%
- Target range width
- 40.4%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- September 22, 2026
- Valid through
- September 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Halozyme Therapeutics?
Halozyme Therapeutics has a verified Buy consensus. The same dataset has an average price target of $99.56.
How far are Halozyme Therapeutics's low and high targets from the recorded price?
The low target implies -37.2%, while the high target implies +3.2%.
How many analysts are included in Halozyme Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Halozyme Therapeutics's target upside or downside calculated?
The average target of $99.56 is divided by the recorded price of $111.45, then one is subtracted to produce -10.7%. This does not guarantee a future return.
When was Halozyme Therapeutics's analyst forecast verified?
The data was verified on 2026-09-22. The dataset is valid through 2026-09-29.